NRIX · Insider Trading
Nurix Therapeutics, Inc. Common stock
Every open-market purchase and sale reported by NRIX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Christine Ring | Chief Legal Officer | MIXED | — | −$83.70K |
| 2026-09-02 | Christine Ring | Chief Legal Officer | MIXED | — | −$98.61K |
| 2026-09-01 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | −$34.28K |
| 2026-08-05 | Gwenn Hansen | Chief Scientific Officer | Sell | −4,111 | −$100.14K |
| 2026-08-05 | Gwenn Hansen | Chief Scientific Officer | MIXED | — | −$100.80K |
| 2026-08-04 | Hans van Houte | Chief Financial Officer | Sell | −4,761 | −$115.99K |
| 2026-08-03 | Christine Ring | Chief Legal Officer | MIXED | −10,802 | −$331.90K |
| 2026-07-30 | Hans van Houte | Chief Financial Officer | MIXED | +7,335 | −$66.52K |
| 2026-07-30 | Christine Ring | Chief Legal Officer | MIXED | +6,333 | −$89.95K |
| 2026-07-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | +6,333 | −$89.95K |
| 2026-07-02 | Christine Ring | Chief Legal Officer | MIXED | — | −$199.19K |
| 2026-06-25 | Gwenn Hansen | Chief Scientific Officer | Sell | −5,394 | −$107.88K |
| 2026-06-25 | Christine Ring | Chief Legal Officer | MIXED | — | −$347.66K |
| 2026-06-02 | Christine Ring | Chief Legal Officer | MIXED | −4,726 | −$128.89K |
| 2026-05-15 | Roger D Dansey | Director | A | +31,250 deriv. | — |
| 2026-05-15 | Anil Kapur | Director | A | +31,250 deriv. | — |
| 2026-05-15 | David L. Lacey | Director | A | +31,250 deriv. | — |
| 2026-05-15 | Judith A Reinsdorf | Director | A | +31,250 deriv. | — |
| 2026-05-15 | Edward C Saltzman | Director | A | +31,250 deriv. | — |
| 2026-05-15 | Paul M Silva | Director | A | +31,250 deriv. | — |
| 2026-05-15 | Roy D. Baynes | Director | A | +31,250 deriv. | — |
| 2026-05-15 | Julia P Gregory | Director | A | +31,250 deriv. | — |
| 2026-05-05 | Hans van Houte | Chief Financial Officer | Sell | −14,055 | −$233.32K |
| 2026-05-04 | Christine Ring | Chief Legal Officer | Sell | −8,148 | −$138.21K |
| 2026-05-01 | Christine Ring | Chief Legal Officer | Sell | −5,394 | −$90.41K |
| 2026-04-02 | Christine Ring | Chief Legal Officer | Sell | −8,148 | −$124.15K |
| 2026-03-02 | Christine Ring | Chief Legal Officer | Sell | −8,148 | −$125.79K |
| 2026-02-10 | Gwenn Hansen | Chief Scientific Officer | A | +136,625 deriv. | — |
| 2026-02-10 | Arthur T Sands | President, CEO | A | +562,500 deriv. | — |
| 2026-02-10 | Christine Ring | Chief Legal Officer | A | +136,625 deriv. | — |
| 2026-02-10 | Hans van Houte | Chief Financial Officer | A | +136,625 deriv. | — |
| 2026-02-09 | Christine Ring | Chief Legal Officer | Sell | −14,261 | −$237.62K |
| 2026-02-03 | Gwenn Hansen | Chief Scientific Officer | M | +31,333 | +$26.32K |
| 2026-01-30 | Hans van Houte | Chief Financial Officer | MIXED | +7,835 | −$60.77K |
| 2026-01-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | +6,921 | −$81.25K |
| 2026-01-30 | Christine Ring | Chief Legal Officer | MIXED | +6,113 | −$73.38K |
| 2026-01-20 | Christine Ring | Chief Legal Officer | MIXED | — | −$62.28K |
| 2025-12-18 | Christine Ring | Chief Legal Officer | MIXED | — | −$60.32K |
| 2025-11-24 | Christine Ring | Chief Legal Officer | MIXED | — | −$571.76K |
| 2025-11-10 | Roger D Dansey | Director | A | +50,000 deriv. | — |
| 2025-11-03 | Hans van Houte | Chief Financial Officer | Sell | −6,284 | −$78.93K |
| 2025-10-30 | Hans van Houte | Chief Financial Officer | MIXED | +8,364 | −$40.05K |
| 2025-10-30 | Christine Ring | Chief Legal Officer | MIXED | +6,888 | −$46.63K |
| 2025-10-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | +7,728 | −$52.30K |
| 2025-10-23 | Gwenn Hansen | Chief Scientific Officer | A | +20,000 deriv. | — |
| 2025-09-17 | Julia P Gregory | Director | M | +10,750 | +$20.00K |
| 2025-08-01 | Hans van Houte | Chief Financial Officer | Sell | −5,402 | −$59.60K |
| 2025-07-30 | Hans van Houte | Chief Financial Officer | MIXED | +7,190 | −$51.70K |
| 2025-07-30 | Gwenn Hansen | Chief Scientific Officer | MIXED | +7,507 | −$51.74K |
| 2025-07-30 | Christine Ring | Chief Legal Officer | MIXED | +6,691 | −$46.13K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Gwenn Hansen | Chief Scientific Officer | 118,679 | $2.65M |
| Hans van Houte | Chief Financial Officer | 40,166 | $897.71K |
| Julia P Gregory | Director | 10,750 | $240.26K |
| Christine Ring | Chief Legal Officer | 9,110 | $203.61K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NRIX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.